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1. Introduction 
Recent advances in molecular biology have led to new insights in the development, growth 
and infiltrative behaviors of primary brain tumors (Demuth and Berens, 2004; Huse and 
Holland, 2010; Johnson et al., 2009; Kanu et al., 2009). These tumors are derived from 
various brain cell lineages and have been historically classified on the basis of 
morphological and, more recently, immunohistochemical features with less emphasis on 
their underlying molecular pathogenesis (Huse and Holland, 2010). The detailed molecular 
characterization of brain tumors has laid the groundwork for augmentation of standard 
treatment with patient-specific designed targeted therapies (Johnson et al., 2009; Kanu et al., 
2009). Nevertheless, these tumors are extremely aggressive in their infiltration of brain tissue 
(Altman et al., 2007; Hensel et al., 1998; Yamahara et al., 2010), as well as in their metastasis 
outside of brain (Algra et al., 1992). Further, it now appears that the physiological conditions 
of the normal brain itself constitute a biological environment conducive to the uncontrolled 
dissemination of primary tumors (Bellail et al., 2004; Sontheimer, 2004). This review surveys 
the latest research on the invasive behavior of two major types of primary brain tumors: 
gliomas and medulloblastomas - the most common tumors diagnosed within adult and 
pediatric brain, respectively (Rickert and Paulus, 2001). The material has been divided into 
five sections: i) Characteristics of malignant brain tumors; ii) Mechanisms of tumor cell 
migration; iii) Models for the study of brain tumor invasion in vivo and ex vivo; iv) Models 
for the study of brain tumor invasion in vitro; and v) Future prospects of anti-invasive brain 
tumor therapy. 
2. Characteristics of malignant brain tumors 
Gliomas, commonly found in the anterior cerebral hemisphere, are a group of tumors 
derived from glial cells - the most abundant cells in the brain (Larjavaara et al., 2007; Lim et 
al., 2007; Louis et al., 2007). They are classified based on well-characterized histological 
features (Louis, 2006; Scheithauer, 2009; Trembath et al., 2008). The World Health 
Organization (WHO) defines gliomas by cell type, location and grade, and categorizes them 
into four classes (Lassman, 2004): i) Grade I tumors, or pilocytic astrocytomas; ii) Grade II 
tumors, also called low-grade astrocytomas; iii) Grade III tumors, or anaplastic 
astrocytomas; and iv) Grade IV tumors, also known as glioblastoma multiforme (GBM). 
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Grade I tumors typically do not invade surrounding brain and are often curable with 
surgery, while tumors of grades II to IV are diffuse and invade normal brain, with grade III 
and IV tumors being most aggressive. Grade III and IV tumors are called “high-grade” or 
“malignant” tumors although they almost never metastasize to other tissues of the body 
(Lassman, 2004).  
The etiological events causing glioma formation have not been clearly defined, but are 
thought to involve genetic alterations (Figure 1A). Such alterations disrupt cell cycle arrest 
pathways (Zhou et al., 2005; Zhou et al., 2010), and cause aberrant receptor tyrosine kinase 
activity in the brain cells (Dai et al., 2001). For instance, activation of receptors such as 
Hepatocyte Growth Factor Receptor (HGF) c-Met (Gentile et al., 2008), Platelet-Derived 
Growth Factor Receptor (PDGFR) (Cattaneo et al., 2006; Natarajan et al., 2006), and 
Epidermal Growth Factor Receptor (EGFR) (Chicoine and Silbergeld, 1997) is now well-
known to stimulate glioma motility. Additionally, marker specific glial progenitor 
populations, neural stem cells and cancer stem cells are being investigated for their roles as 
possible initiators of gliomagenesis (Briancon-Marjollet et al., 2010). 
 
 
Fig. 1. Origin of brain tumors: development gone wrong. (A) During normal brain 
development, neural stem cells give rise to three main adult cell types: neurons, 
oligodendrocytes and astrocytes. Genetic alterations occur within these differentiated cells 
that can lead to the rise of malignant tumors. Alternatively, immature stem cells may serve 
as cancer stem cells that confer both radio- and chemoresistance phenotypes to gliomas. (B) 
Medulloblastomas originate in the cerebellum, from granule neuron precursor cells 
(GNPCs), upon un-controlled activation of Sonic Hedgehog (Shh) signaling pathway. 
The current standard of care for gliomas is surgical removal of the tumor followed by post-
operative radio- and chemotherapy (Stupp and Weber, 2005). However, due to their 
diffusely invasive properties, gliomas are one of the most difficult tumors to isolate or treat 
(Burger et al., 1985). Furthermore, while cell migration is fundamental to normal brain 
development and homeostasis, unconstrained migration of pathological and diseased cells 
makes the complete resection of tumor lesions, often performed for other types of tumors, 
an ineffective clinical treatment in brain. Prior to the advance of high-throughput genetic 
screening techniques clinicians depended primarily on glioma recurrence for prognosis of 
patient survival. Later, the generation of models that combined gene expression and 
molecular markers made it possible to subcategorize gliomas, enabling the increase in 
www.intechopen.com
 Migration and Invasion of Brain Tumors 
 
227 
grade-specific predictability (Zhou et al., 2010). Recent findings suggest the possibility that 
the recurrent growth of glioma is derived from chemo- and radio-resistant cancer stem cell 
renewal and/or growth of diffusively invasive cells (Hadjipanayis and Van Meir, 2009). 
Evidence emerging over the past decade has suggested the existence of stem-like cells 
within brain tumors, which are currently examined as potential sources of tumor resistance 
and recurrence (Galli et al., 2004; Lenkiewicz et al., 2009; Singh and Dirks, 2007). The 
inability to remove high-grade gliomas in their entirety, or to prohibit their migration to 
other parts of the brain has led to low survival rates among brain cancer patients (Demuth 
and Berens, 2004).  Patients with GBM have a median survival of about 1 year, while 
patients with anaplastic gliomas can survive 2-3 years, and those with grade II gliomas often 
survive 10-15 years (Louis et al., 2007).  
Medulloblastomas (MBs) encompass a collection of clinically and molecularly diverse tumor 
subtypes, and are characterized by high tumor invasiveness to extraneural tissues and 
reoccurrence in the cerebellum after total resection (Dhall, 2009). Four different MB subtypes 
have been included in the current WHO classification (Louis et al., 2007): i) Classic MB; ii) 
Demoplastic/nodular MB; iii) MB with extensive nodularity;  and iv) Anaplastic or large cell 
MB. Two other variants, medullomyoblastoma and melanotic MB, are much more rare. MBs 
are overwhelmingly found in pediatric patients, but can rarely occur within adult brain, 
where the tumor characteristics become very atypical. Adult MB is arguably a biologically 
distinct challenge in that it exhibits a higher proportion of desmoplastic histological 
characteristics, shows more proclivity toward cerebellar hemispheric origin, possesses 
different proliferative and apoptotic indices, and demonstrates a notorious tendency for late 
relapse with respect to the pediatric variants (Chan et al., 2000; Sarkar et al., 2002). 
MBs are thought to arise within the cerebellum, with approximately 25% originating from 
granule neuron precursor cells (GNPCs) (Gibson et al., 2010) after aberrant activation of the 
Sonic Hedgehog (Shh) pathway (Figure 1B). A number of genetic alterations have been 
associated with MB (Biegel et al., 1997; Bigner et al., 1997; Herms et al., 2000; Yin et al., 2002). 
Studies of the receptors and intracellular signaling pathways that support proliferation and 
survival of GNPCs have shown a dysregulation of the Shh pathway, the canonical Wnt 
pathway, or the ERB-B pathway in both familiar and sporadic MBs (Gilbertson, 2004). A 
recent study showed that Wnt-subtype tumors infiltrate the dorsal brainstem, whereas Shh-
subtype tumors are located within the cerebellar hemispheres (Gibson et al., 2010). These 
results have profound implications for future research and treatment of this childhood 
cancer, because to date, few data link such genetic alterations to metastasis in MB.  
The treatment of patients with standard risk tumors, i.e. those who had tumors completely 
resected and with no evidence of dissemination to any other part of the body (Nishikawa, 
2010), has been partially successful with survival rates of up to 40% for gliomas over the last 
five years (Van Meir et al., 2010) and 78% for MBs (Gajjar et al., 2006). In contrast, the cure of 
metastatic disease has been limited until recently to single cases (Fruhwald and Plass, 2002). 
Even though promising, the current treatment options for high-risk brain tumors are 
associated with neural and neuroendocrine side effects, with a tremendous decline in 
quality of life among survivors (Edelstein et al., 2011; Palmer et al., 2001), as well as growth 
reoccurrence and aggressive brain infiltration (Farin et al., 2006).   
In the cases of both gliomas and MBs, the migration of cells from primary tumors to other 
locations, within brain or otherwise, has been one of the most clinically challenging and 
poorly understood processes that contributes to the poor life prognosis of patients. The 
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following sections will discuss the fundamental mechanisms of cellular migration, the 
common in vivo models used to examine tumor cell migration within brain, and current in 
vitro technologies used to characterize and better understand the migration of cells derived 
from gliomas and MBs. 
3. Mechanisms of tumor cell migration  
The migration of brain cancer cells is highly complex, involving interactions with 
extracellular matrix (ECM), and chemoattractants that either diffuse from blood vessels 
and/or are produced by neighboring cells (Condeelis and Segall, 2003; Sahai, 2005). As a 
consequence of such complexity, the molecular mechanisms of primary brain tumor 
migration and metastasis are poorly understood. Over the last several years, a group of 
critical growth factors has been the topic of research for their role as regulators of tumor 
biology and chemotaxis  (Hamel and Westphal, 2000). It is believed that over time secreted 
cytokines diffuse and generate concentration gradients that are sensed by glioma and MB-
derived cells, leading to the detachment and migration of these cells away from the primary 
tumor (Chicoine and Silbergeld, 1997; Piperi et al., 2005). Therefore, brain tumor invasion is 
believed to be induced by soluble cytokines that stimulate directional and/or random tumor 
cell motility (Brockmann et al., 2003). Alternatively, cancer cells may communicate with 
specific distant targets through secreted microvesicles that contain growth factors and 
receptors, functional mRNAs, and miRNAs (Cocucci et al., 2009; Skog et al., 2008; Valadi et 
al., 2007). Such microvesicles are shed by most cell types, including cancer cells, and have 
been found in sera from numerous cancer patients (Cocucci et al., 2009; Skog et al., 2008). 
While the effects of mitogens on the in vitro motility and invasion of glioma cells have been 
well documented using conventional assays, such as transwell chambers and spheroid 
models (discussed later in this chapter), the ability of soluble cytokines to drive various 
cellular functions (i.e. migration and/or proliferative growth) has been shown to depend 
upon several determinant factors. Some of these factors have been addressed in the 
literature, such as dosage-dependence (Gonzalez-Perez and Quinones-Hinojosa, 2010; Shih 
et al., 2004), contact inhibition (Weidner et al., 1990), as well as autocrine and paracrine 
signaling-driven tumor growth via extensive proliferation and aggressive recruitment of 
surrounding cells to the tumor (Betsholtz et al., 1984; Fomchenko and Holland, 2005; 
Hermansson et al., 1988; Rood et al., 2004). The diligent study of Central Nervous System 
tumor cell (CNSTC) invasion has identified four commonly overexpressed receptor tyrosine 
kinases as targets for anti-invasive therapies (EGFR, c-MET, PDGFR, and Vascular 
Epidermal Growth Factor Receptor (VEGFR)) (Abounader, 2009; Arora and Scholar, 2005; 
Huang et al., 2009; Zwick et al., 2001). 
Cancer cell locomotion is highly sensitive to stimuli from the ECM as well as from the 
surrounding media. Receptors on the plasma membrane can activate cellular signaling 
pathways that alter the mechanotransduction of a cell via reorganization of motility-related 
organelles and cellular compartments. As an example, tumor-derived cells are known to 
increase cell motility in response to protease inhibitors and adhesion inhibitors (Sahai, 2005). 
The modes of cancer cell migration vary according to whether the cells undergo single cell 
chain, or collective migration. Tumor-derived cells disseminate from the bulk tumor mass 
individually via mesenchymal or amoeboid movement. However, in many tumors both 
single cell and collective cell migration may be present depending on the molecular cues 
dictating migration (Friedl and Wolf, 2003). 
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During the mesenchymal-type migration often observed in gliomas, cells exhibit a highly 
polarized and fibroblastic morphology. Cells undergo the classical, overlapping processes 
generally exhibited during mammalian cell migration: cell polarization, protrusion of 
leading edge, traction at the trailing edge, and detachment (Lauffenburger and Horwitz, 
1996). First, cells become highly fibroblast-like, with bipolar opposites. Second, a growing 
number of actin filaments begin to push the cell membrane outwards on the leading edge 
via the formation of lamellipodia or filopodia. Actin polymerization then initiates signal 
transduction pathways along the leading edge. Next, cell integrins come into contact with 
ECM ligands and cluster to recruit intracellular signaling proteins that induce 
phosphorylation signaling, or so-called “outside in” signaling (Hynes, 2002; Miyamoto et al., 
1995) via focal adhesion kinases. Afterwards, surface proteases act to cleave ECM molecules 
via production of soluble matrix metalloproteases (MMPs) in order to degrade surrounding 
ECM. Finally, cell contraction occurs via myosin that leads to focal contact disassembly at 
the trailing edge and actin cleavage and filament turnover (Wear et al., 2000).  
Contrarily, during amoeboid movement, cells utilize a “fast gliding” mechanism driven by 
weak interactions with the substrate. As such, cells like neutrophils and lymphocytes exhibit 
a shape-driven migration with appreciable lack of focal adhesions that allows them to 
circumnavigate rather than degrade surrounding ECM during migration (Friedl et al., 2001). 
The result is an increased cell motility, as well as cell ability to undergo early detachment 
and metastatic spread from primary tumors. Cancer cells may undergo conversion from 
mesenchymal to amoeboid type migration in order to alter integrin distribution and actin 
cytoskeleton organization for increased dissemination (Wolf et al., 2003). 
Collective migration is a well-studied phenomenon that is characteristic of embryological 
development, such as during the migration of cell clusters or sheets in the ectoderm following 
closure of the neural tube (Davidson and Keller, 1999). In vitro studies (Friedl et al., 1995; 
Nabeshima et al., 1995) showed that cells can migrate as a functional unit, and that in contrast 
to single motile cells, cell-cell adhesion can lead to a particular form of cortical actin filament 
present along cell junctions. This enables formation of a larger, multicellular contractile body. 
Here, a select group of highly motile cells are designated as so-called “path-generating” cells 
that create migratory traction via pseudopod activity (Friedl et al., 1995; Hegerfeldt et al., 2002; 
Nabeshima et al., 1995). It is then believed that cells located in the inner and trailing regions 
are passively dragged behind during dissemination. In tumors, collective migration has been 
observed as protruding sheets that maintain contact with the primary site, or as cell clusters 
that detach from their origin and extend along paths of least resistance (Byers et al., 1995; 
Hashizume et al., 1996; Madhavan et al., 2001). Collective migration offers the advantage of 
protection from immunological response. Further, heterogeneous sets of cells that move as one 
functional unit can work together to promote the invasion of less motile, but potentially 
apoptosis-resistant, sub-populations that increase tumor survival. To complicate matters, cells 
may transition between collective and individual cell migration with dedifferentiated cells to 
increase dissemination and metastatic spread (Friedl and Wolf, 2003).  
4. Models for the study of brain tumor invasion in vivo and ex vivo 
Glioma and MB models have been largely developed by studying altered oncogene 
expression through retroviral transfection of murine neural tissue of genetically engineered 
mouse models (GEMMs) (Fisher et al., 1999; Hatton et al., 2008; Heyer et al., 2010; Huse and 
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Holland, 2010; Pazzaglia et al., 2002; Pazzaglia et al., 2006; Romer and Curran, 2004). Via this 
powerful methodology, diverse tumor types with distinct histological features have been 
generated dependent upon the specific genetic background of the cell of tumor origin and 
the disease location of interest (Furnari et al., 2007). In particular, the histological features of 
GEMM and implanted xenograph derived tumors have been shown to be similar to human 
brain tumors presented in identical CNS locations, and have shed light on the diverse nature 
of human gliomas found clinically (Candolfi et al., 2007).   
Historically, it has been suggested that glioma cell infiltration throughout the brain 
primarily utilizes mechanisms of migration innately patterned by neural progenitors during 
normal brain development (Cayre et al., 2009; Kakita and Goldman, 1999; Scherer, 1940). 
Confirmation of this similarity has been accomplished in vivo via implanted xenographs that 
result in spontaneous intracranial GBMs in six different animal model variations that show 
reproducible invasion of tumor cells into non-neoplastic brain regions (Figure 2) (Candolfi et 
al., 2007). More recently, several labs began utilizing GEMMs to specifically examine glial 
progenitor recruitment in vivo (Assanah et al., 2006; Masui et al., 2010). For instance, 
Assanah and colleagues have demonstrated via histological analysis of cortical sections from 
GEMMs that overexpression of tumor inducing proteins like PDGF can induce malignant 
glioma cells to invade across the corpus callosum into the contralateral hemisphere and 
overlying cortex (Assanah et al., 2006; Assanah et al., 2009). 
The diffusive invasion and increased recurrence of gliomas post-operatively have been 
attributed to the same therapies used to treat the disease. Narayana and colleagues reported 
clinical results of 61 high-grade GBM patients treated with an anti-angiogenesis drug, 
bevacizumab. Their results showed that 82% of the patients treated with bevacizumab suffer 
from tumor regrowth and 70% died from the disease within 19 months (Narayana et al., 
2009). Pàez-Ribes and colleagues reported similar results showing that although the use of 
angiogenesis inhibitors, such as Sunitinib and SU10944, extend that survival time of treated 
mice to an additional 7 weeks versus non-treated mice, the kinase inhibitors tend to also 
evoke an increase in glioma cell invasion as well as to promote tumor progression (Pàez-
Ribes et al., 2009). A closer examination using xenographs of human tumor spheroid 
implanted into rat brains, and further treated with the bevacizumab, led to a reduction in 
contrast enhancement in magnetic resonance imaging (MRI) analysis while enhancing 
glioma cell diffusion by 68% versus non-treated rats (Figure 3) (Keunen et al., 2011). 
Characterization of MB migration in vivo has yet to be analyzed at large, as most of the 
reports to-date focused on tumor growth and not its dissemination. Nevertheless, a select 
number of in vivo studies examined tumor cell migration and invasion. Hatton and 
colleagues illustrated in a GEMM for MB that 94% of the mice developed MB by 2 months of 
age, and that these tumors frequently exhibited leptomeningeal spread, a common feature of 
the human disease (Hatton et al., 2008). MacDonald and colleagues implanted human MB 
cells in the brain of nude mice, and thereafter followed them in vivo at single-cell level via 
fluorescence microscopy (MacDonald et al., 1998). These MB cells were shown to invade the 
brain and to form distant micro-metastases. In another study, MB cells were engineered to 
overexpress HGF and were implanted subcutaneously and intra-cranially (Li et al., 2005). 
The study reported activated c-Met that strongly increased MB xenograft growth and 
invasive characteristics with finger-like protrusions, metastatic growth, and leptomeningeal 
spread. Such findings illustrate that the HGF/c-Met pathway is one of the mediators of MB 
malignancy.  
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Fig. 2. Neoplastic cellular infiltration into surrounding non-neoplastic brain tissue in 
syngeneic rat (CNS-1) and mouse (GL26) GBM models and human glioma xenografts in 
nude mice (U251 and U87). Paraffin sections (5 μm) from GBM were stained with 
hematoxylin and eosin for evaluating neoplastic invasion. The numbers in low-
magnification microphotographs depict areas magnified in the microphotographs on the 
right. Arrows indicate malignant cells, clusters of GBM cells, and tumoral blood vessels 
infiltrating surrounding brain parenchyma. The indistinct tumor borders and the malignant 
cells clearly entering the non-neoplastic brain tissue suggest an invasive phenotype. 
(Courtesy of Candolfi et al., 2007) 
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Fig. 3. Changes in blood vessel morphology and tumor cell invasion after bev treatment. 
Immunostaining for von Willebrand factor (vWF) (A and B) and quantification thereof (C), 
indicating a significant reduction in the density of medium and large blood vessels and in 
total vessel number after bev treatment. (Scale bar: 200 μm.) Nestin-stained composite 
images (D and E) reveal a more homogeneous appearance of the treated compared with 
untreated tumors, also reflected in corresponding T2-weighted MRI images (F). Large 
vessels (“V”) appear as dark tortuous lines in nestin and T2- weighted images and necrotic 
areas (“N”) as brighter spots. Quantification of the nestin-positive cells outside the tumor 
core (G and H) shows a 68% increase in cell invasion after treatment (I). mi.v: microvessels; 
in.v: intermediate-sized vessels; ma.v: macrovessels; Ctrl: controls; Tr: treated. (Scale bars: ± 
SE.) ***P < 0.001. (Courtesy of Keunen et al., 2011) 
The ability to visualize brain tumor invasion in direct response to specific genetic 
aberrations and alterations made to the immediate environment has been critical in 
understanding the characteristics of this process. An advance made in this direction was 
accomplished via the detection of specific biomarkers involved in the progression or 
migration of CNSTCs, such as Receptor Tyrosine Kinases (RTKs), using conjugated 
antibodies that enabled in vivo monitoring via MRI (Towner et al., 2008). Alternatively, to in 
vivo imaging procedures, ex vivo brain tumor invasion assays that enable the study of tissue 
outside of the living system have had a tremendous impact in the field. Brain slices from 
mice and rats have been used to quantify the invasion of human gliomas (Nakada et al., 
2004), and have demonstrated suppressed invasion on 2D surfaces, suggesting that the brain 
environment alone is capable of regulating protein function and, consequentially, the 
pattern and directionality of glioma migration (Beadle et al., 2008). Additionally, not only 
have ex vivo cell cultures been used to study the invasive properties of CNS tumors, but also 
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to characterize the expression molecular markers (Riffkin et al., 2001), and to evaluate the 
therapeutic potential of co-cultured T-cells for anti-tumor activity (Ahmed et al., 2007).    
By reducing the incidence of recurrent growth, clinicians envision the possibility of 
detecting and directly tracking migratory tumor cells in vivo, and therefore enabling 
operative procedures limited to a single total resection surgery. In order to accomplish this 
goal, there is a stringent need for development of enhanced imaging tools to allow 
visualization of migrating tumor cells. Meanwhile, the most successful quantitative 
assessment of CNSTCs migration has been accomplished outside of the brain itself, in 
engineered systems redesigned to mimic specific in vivo conditions. We will discuss these in 
vitro assays further, which have been utilized to evaluate a variety of cellular functions, from 
growth patterns and rates, to invasive motility of cells derived from highly malignant brain 
tumors. 
5. Models for the study of brain tumor invasion in vitro  
Tumor cells of the brain have been characterized as having a highly infiltrative phenotype 
for spreading into the healthy surrounding parenchyma. This malignant property is 
arguably the principle reason for tumor recurrence and high mortality rates (Lim et al., 
2007). The interaction of integrins, membrane anchored heterodimeric proteins, with various 
ECM proteins has been explored extensively, as it is one of the key events that occurs during 
the invasion of tumor cells within their local microenvironments (Teodorczyk and Martin-
Villalba, 2010). Another key process of tumor invasion is the cellular secretion/production 
of proteases that degrade ECM proteins in order to create pores through which the cells may 
migrate; such proteases include serine proteases, various MMPs, and cathepsins (Rao, 2003). 
In addition to stimulating tumor invasion via degradation of ECM protein components, it is 
assumed that MMPs are capable of enhancing tumor growth by indirectly triggering the 
release of growth factors trapped within the basement membrane itself (Mott and Werb, 
2004). Lastly, another key aspect of tumor dissemination is played by the activation of RTK 
signaling pathways. During the destruction of the basement membrane by MMPs, soluble 
growth factors are sequestered from the ECM and bind to their cognate cellular receptors to 
trigger a cascade of events that enhance cellular migration (Zucker et al., 2000).  
In vitro invasion assays are important tools for investigating the tumor-matrix interactions 
and the effects of extracellular macromolecules on these interactions. While not entirely 
identical to in vivo behavior, the study of tumor cell migration in vitro is advantageous due 
to the tightly-controlled experimental conditions, higher experimental throughput, and 
lower costs. The following section discusses the most commonly used in vitro assays, in the 
order of increased complexity.  
5.1 Culture dish assays 
Culture dish assays have the advantage of design simplicity and execution, while providing 
insightful information pertaining to cell-to-cell and cell-to-environment interactions. Coated 
culture dishes have been widely used to examine the roles played by specific ECM proteins, 
integrins, MMPs, and RTKs in stimulating the migration of brain tumor-derived cells, as 
detailed here.  
Integrins are membrane heterodimeric proteins that mediate cell-environment attachment 
(Hynes, 1987; Tucker, 2006). In addition to anchoring cells to their environment, integrins 
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have been shown to serve as signal mediators for ECM proteins that were found to stimulate 
tumor migration in vitro (Ohnishi et al., 1997; Tysnes et al., 1996). The most abundant ECM 
proteins found to interact with integrins in the brain are fibronectin, laminin, fibrinogen, 
tenascin-C, thrombodpondin, neuron-glia cell adhesion molecules (Ng-CAMs), and 
collagens IV and V (Rutka et al., 1988). Giese and colleagues evaluated astrocytoma 
migration as a function of integrin adhesiveness on various ECM proteins (collagen IV, 
fibronectin, laminin and vitronectin) (Giese et al., 1994). Based on the examination of eight 
different astrocytoma cell lines, the group concluded that the migration of glioma cells was 
subject to alteration depending on tumor expressed integrins and the availability of 
complementary matrix proteins. Furthermore, even though laminin frequently enabled 
tumor cells to adhere and migrate with increased adhesion, overall it was stated that there 
was no specific ECM protein that would always result in increased astrocytoma binding 
(Giese et al., 1994).  
Friedlander and colleagues examined the migration trends of twenty-four excised human 
astrocytomas, ten GBM cell lines, and three MB cell lines on nine different ECM protein 
coated culture dishes (Friedlander et al., 1996). The comparative migration of astrocytomas 
(grades I, II and III), GBMs and MBs demonstrated that most tumor cells, regardless of their 
grade, were capable of migrating on fibronectin and laminin at rates exceeding 30 μm over a 
16 hour period. A closer comparison between low-grade and high-grade tumor migration 
on all tested substrates revealed that, on average, high-grade tumors migrated 
approximately 14 μm more than low-grade tumor cells under similar conditions. 
Specifically, type IV collagen substrates induced a 4-fold increase in distances traveled by 
high-grade tumor cells over low-grade cells. Collagen IV coated substrates also stimulated 
approximately 100 μm migration over 16 hours of thirteen excised GBMs and eight well 
studied GBMs cell lines, with cell lines being more motile than the excised tumors 
(Friedlander et al., 1996). Finally, monoclonal antibodies specific for the v and 1 integrins 
were used to reduce the migration of four GBMs cell lines (U-373 MG, U-118 MG, U-251 MG 
and U-87 MG) on several migration enhancing ECM substrates, including collagen IV 
(Friedlander et al., 1996). These results illustrate that brain tumor-derived cells can migrate 
remarkably large distances within the brain, often to varied regions of the brain. However, 
tumor cell populations are very diverse, and such studies have not identified the lineage of 
motile cells, or whether certain sub-populations of cells could migrate farther than others 
within brain. 
MB samples revealed type I collagen present in the leptomeninges, and in the ECM 
surrounding blood vessels and tumor cells (Liang et al., 2008). Expression of both type I 
collagen and 1 integrin, a subunit of a known type I collagen receptor, localized to the same 
area of MB. The same study showed that the adherence of MB cells to type I collagen matrix 
in vitro depends on the presence of 1 integrin (Liang et al., 2008). 
A study by Corcoran and Del Maestro revealed that MB cell lines do not defer cell 
proliferation for migration across an uncoated surface or invasion of a type I collagen 
matrix, contrary to the “Go or Grow” hypothesis (Corcoran and Del Maestro, 2003). The “Go 
or Grow” hypothesis proposes that cell division and cell migration are temporally exclusive 
events, and that tumor cells defer cell division to migrate (Giese et al., 1996). Migrating and 
invading MBs continued to proliferate and migrate/invade, irrespective of the number of 
divisions that took place (Corcoran and Del Maestro, 2003). These findings emphasize the 
need to evaluate the effect of future therapies on both biological events and, if possible, to 
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identify intracellular signaling proteins that negatively regulate MB migration/invasion and 
proliferation. 
Matrix-degrading proteases are involved in the hydrolytic breakdown of ECM proteins and 
have been shown to regulate tumor cell progression and invasion (Levicar et al., 2003; Rao, 
2003; Rooprai and McCormick, 1997). Additionally, proteases have been well-studied and 
shown to display differential expression and activation patterns, correlated to their 
invasion-associated effects, i.e. angiogenesis (Forsyth et al., 1999; Thorns et al., 2003). These 
proteases are either located in the membrane of the cell or secreted into its surroundings, 
respectively denoted as MT-MMP and MMP. Diffusely invasive glioma cells express MMPs 
that enable them to catabolize ECM proteins that have been shown to prohibit the migration 
of other cells that lack these MMPs. For instance, specific membrane proteins expressed by 
CNS myelin have been shown to have anti-spreading functionality on neurite outgrowth, 
astrocytes and fibroblasts (Schwab and Caroni, 1988; Spillmann et al., 1998).  
The migration of glioma-, MB- and meningioma- cell lines on CNS myelin was found to be 
tumor grade-dependent and to involve active unspecified MMPs (Amberger et al., 1998). 
Culture dishes were coated with 15 g/dish rat spinal cord myelin, a concentration shown 
to reduce by 80% the fibroblast migration, followed by the seeding with various cell lines 
and the recording of cell ability to adhere and spread (Amberger et al., 1998). The results 
conclude that high grade GBMs, like U-251 MG, were able to strongly attach and spread, 
while low grade gliomas and MBs exhibited poor attachment and inhibited spreading 
(Amberger et al., 1998). Additionally, spreading of GBM and anaplastic astrocytomas cells 
on CNS myelin was strongly blocked when cells were treated with the MMP blocker O-
phenanthroline (Felber et al., 1962), and temporarily inhibited with carbobenzoxy-Phe-Ala-
Phe-Tyr-amide (Amberger et al., 1997) confirming the role played by MMPs in ECM 
modification as a precursory for migration.   
Belien and colleagues studied the role of MT1-MMP in enhanced spreading and migration 
of gliomas (Belien et al., 1999). As a substrate, they utilized myelin-coated culture dishes, 
since it was previously shown that invasion of gliomas predominantly occurs along the 
white matter of the CNS (Giese et al., 1996; Pedersen et al., 1995), which is heavily composed 
of myelin (Baumann and Pham-Dinh, 2001; McLaurin and Yong, 1995), to seed both gliomas 
and MT1-MMP-transfected fibroblasts. In this case, MT1-MMP was shown to be responsible 
for altering the cellular environment to enable migration of both gliomas and the transfected 
fibroblasts (Belien et al., 1999).  
When the invasiveness of five MB cell lines within a 3D in vitro collagen I or IV-based model 
was studied, the data showed that within hours of implantation, individual cells readily 
detached from the surface of the cell aggregates and invaded the collagen matrix, to 
distances of up to 1,200 µm and at rates of up to 300 µm per day (Ranger et al., 2010).  
Furthermore, MB invasiveness within this 3D model appears to depend upon a combination 
of metalloproteinase (MMP-1 and -2, TIMP-1 and -2) and cysteine protease activity (Ranger 
et al., 2010). 
The RTKs, like integrins, function as signal mediators of extracellular proteins yet in a 
different way. Integrins, as mentioned above, interact primarily with static, structural ECM 
proteins that are the composite materials of the cellular environment (Tucker, 2006). 
Meanwhile, RTKs interact with soluble macromolecules present in the environment, e.g. 
growth factors, that trigger a cascade of events in the cells, spanning from the extracellular 
surface of the plasma membrane to the nucleus, to elicit various cellular responses (Konopka 
and Bonni, 2003; Mueller et al., 2003; Teodorczyk and Martin-Villalba, 2010). Additionally, 
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genetically modified and overexpressed RTKs are capable of eliciting cellular signals in the 
absence of ligand binding, thus bypassing the need for an extracellular trigger (Akbasak and 
Sunar-Akbasak, 1992; Dong et al., 2011; Strommer et al., 1990; Torp et al., 2007). Ding and 
colleagues employed U-87 MG cells grown on coated cultured dishes to demonstrate a 
strong adhesion to vitronectin, as opposed to collagen or laminin, which was mediated 
through the v3 and v5 integrins (Ding et al., 2003). Additionally, the group was able a to 
link the specific cooperative interaction between the RTK PDGFR and the v3 integrin to 
induce migration of U-87 MG cells into the wounded area in a scratch-wound assay after 
stimulation of the culture with PDGF (Ding et al., 2003). Therefore, these results suggest the 
direct correlation between the ability of RTKs to transmit extracellular signals into the cell 
and to convert these signals into direct and measurable cellular response.  
As an improvement upon the simple use of cell culture dishes for study of tumor cell 
migration, micropipette turning assays have been used to create gradients within culture 
dishes that enable changes in cell migration with micropipette position. Gradients, defined 
as fields where biochemical concentrations are varied along a specific distance, are 
generated via simple diffusion of biological molecules from the micropipette into the culture 
medium. Gradient formation and stability are functions of the molecular properties of the 
stimulant being used (i.e. diffusivity constant and molecular weight), as well as pipette 
mechanics (i.e. dimensions and flow rates) (Lohof et al., 1992), and for these reasons make 
gradient measurement difficult. Wyckoff and colleagues used the micropipette method to 
collect subpopulations of motile mammary carcinoma and macrophage cells into 
microneedles filled with Matrigel™ and a range of EGF concentrations from confluent 
culture dishes (Wyckoff et al., 2000). The Matrigel™ matrix is a solubilized basement 
membrane preparation extracted from Engelbreth-Holm-Swarm mouse sarcoma (Ohashi et 
al., 2006; Reed et al., 2009), commonly used in cell-matrix interaction studies. The contents of 
the microneedles were then emptied into new culture dishes and allowed to grow for at 
least 6 days before quantifying cell populations. A bell-shaped curve of normalized cell 
numbers was reported and had the maximal number of collected cells for 25 nM EGF, 8-fold 
greater than controls (Wyckoff et al., 2000). Such results illustrate that growth factor 
concentration gradients, or differences in concentrations along given distances, stimulate 
brain tumor cell migration. 
5.2 Spheroids 
A key question regarding cancer cell migration and invasion is based on determining the 
reason why tumor cells detach from the bulk tumor mass. Some studies have suggested that 
lack of contact-inhibition may be responsible for cell migration away from the bulk 
(Pedersen et al., 1995). While normal cells go into a quiescent state that allows apoptosis 
during nutrient depleted states, cancer cells do not rely on contact-dependent growth and 
therefore can detach and venture out to diffusely invade the parenchyma. The Spheroid 
Model utilizes the natural tendency of cancer cells to form colonies and to grow into 
localized spheres (Santini and Rainaldi, 1999; Zhang et al., 2005). This model mimics the 3D 
characteristics of cell migration, while culture dish experiments described in the previous 
subsection provide important data on 2D cell migration. As a result, the spheroid model has 
been used to study the directional migration of tumor cells from the bulk spheroid mass in 
response to specific motogens and chemotherapeutic agents, as well as to measure the 
penetration of various molecules into the tumor (Carlsson and Nederman, 1983; Nederman 
et al., 1983).  
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Spheroids grown from several different GBM cell lines were placed on uncoated 24-well 
dishes and treated with EGF, which triggered a strong stimulation of cellular invasion and 
increased growth (Lund-Johansen et al., 1990). Similarly, spheroids grown from several 
human glioma cell lines exhibited enhanced growth and directional migration when 
cultured in 10 ng/ml EGF or 10 ng/ml bFGF concentrations, compared to control and other 
growth factors, such as PDGFBB (Engebraaten et al., 1993). When MB cultures were induced 
to generate spheroids, gene expression of CD133 (a hallmark of the brain cancer stem cells 
and radioresistant tumors), MT1-MMP, and MMP-9 were induced and correlated with 
increased invasiveness of the spheroid cells (Annabi et al., 2008). Additionally, Corcoran 
and Del Maestro revealed that MB cells from an established cell line, UW228-13, could 
exhibit elevated levels of invasion into a 3D matrix of type 1 collagen compared to biopsied 
DAOY cells (Figure 4) (Corcoran and Del Maestro, 2003). 
 
 
Fig. 4. First and last images extracted from time-lapse videos of DAOY (A and B) and 
UW228-3 (C and D) spheroids invading Type I collagen matrices. Spheroids were recorded 
48 hours after implantation. The numbers identify cells that divided zero, one, or two times 
in 40 hours; parent cells are labeled in A and C and daughter cells in B and D. The number 
of hours elapsed from the start time of the videos (t) are indicated at the top right corner of 
images. Scale bars, 250 μm. (Courtesy of Corcoran and DelMaestro, 2003) 
Wild-Bode and colleagues grew glioma spheroids on agar base-coated culture flasks until 
they were ~200 m in diameter, followed by their transfer to 96-well plates. In order to 
examine the cause of glioma relapse in close proximity to the excised lesion, they measured 
the radial distance of migration as function of irradiation at 3 Gy. Irradiation led to 
increased migration of all cell lines, compared to non-irradiated cells, a phenomenon which 
was linked to increased expression and activation of MMP-2, MMP-9 and MT1-MMP (Wild-
Bode et al., 2001).  
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Just as the spheroid model employs a 3D environment in order to better mimic in vivo 
conditions, other in vitro technologies were developed to imitate the biochemical 
environment of the brain. In particular, transwell assays were developed in order to expose 
tumor-derived cells to different concentration gradients of cytokines present within brain. 
5.3 Transwell migration assays 
The transwell migration assay is a commonly-used test to study the migratory response of 
cells to inducers or inhibitors. This assay is also known as the Boyden or modified Boyden 
chamber assay, and was originally used to evaluate leukocyte chemotaxis (Boyden, 1962). In 
this assay, a chamber that is separated into two compartments by a polyethylene 
terephthalate filter (Figure 5A) and the cells placed into the upper compartment are allowed 
to settle, while the solution being tested for chemotactic activity is placed in the lower 
compartment. The membrane contains randomly distributed pores through which the cells 
migrate (Figure 5B), in response to the chemoattractant from the bottom compartment. 
Invasive cells migrated to the underside of the filter can be stained and quantified (Figure 
5C). 
Different ECM components can be used to coat the filter in order to mimic the basement 
membrane that cells must penetrate while invading in vivo, while exposing the cells to 
various chemicals for different time lengths. The main advantage of this assay is its 
detection sensitivity. Migration through the permeable membrane can be caused by very 
low levels of chemoattractants (Kreutzer et al., 1978). Prolonged studies are difficult, due to 
the fact that the chemoattractant concentration will quickly equalize between the 
compartment below the membrane and the compartment above the membrane. Another 
disadvantage is the relative difficulty in setting up the transwells. Despite these 
disadvantages, transwell assays are commonly the test of choice for migration and invasion 
studies in vitro. 
Over the last 50-years, several modifications have been implemented to this technology by 
various research groups in order to circumvent difficulties encountered with its use. For 
instance, upon crossing the membrane and reaching the lower surface of the chamber, cells 
may detach from the filter, thus resulting in an underestimate of transmigrated cells (Li and 
Zhu, 1999).  Albini and colleagues were among the first researchers to use filters coated with 
ECM. They used radiolabeled proteins to demonstrate an 8-10 hour gradient stabilization 
period within the Boyden chamber, and showed that cell invasion time was very much 
dependent on the volume of the coated matrix barrier (Albini et al., 1987). Li and Zhu 
pioneered the use of different cell populations to attract other cells, by growing a monolayer 
of bovine aortic endothelial cells on filters, and investigating the transendothelial migration 
of six cell lines of different human tumors (Li and Zhu, 1999). 
Chemotactic migration of GMB cells in response to several growth factors, predominately 
PDGF, EGF, and HGF, has been extensively studied (Hoelzinger et al., 2007). These studies 
have demonstrated dosage-dependent motogenic responses to various concentrations and 
combinations of these cytokines (Brockmann et al., 2003). For example, Moriyama and 
colleagues demonstrated, through a checkerboard analysis of various HGF concentrations, 
that a dose-dependent response to HGF induces both chemotaxis and chemokinesis of U-251 
MG cells (Moriyama et al., 1996). In this study the concept of an “optimal concentration” 
was introduced, and the authors reported a decline in the chemotactic activity of U-251 MG 
cells at concentrations exceeding the reported optimal concentration of 50 ng/ml (Moriyama 
et al., 1996). Similarly, Koochekpour and colleagues used transwell assays to show dose-
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dependent migration and invasion of five different human glioma cell lines toward various 
concentrations of HGF, in addition to reducing basal migration of these cells using an anti-
HGF neutralizing antibody (Koochekpour et al., 1997). Brockmann and colleagues reported 
increases in U-87 MG migration, as high as 33-fold greater than controls, in the presence of 
100 pM HGF concentrations. In the same study, 1 nM TGF and 50 nM FGF1 stimulated U-
87 MG migration 17- and 4-fold, respectively (Brockmann et al., 2003). Transwell assays 
were used to demonstrate the chemotaxis of metastatic breast adenocarcinomas toward 
bone and brain extracts, rather than extracts from liver or lung (Hujanen and Terranova, 
1985). Interestingly, it was found that C6-GFP rat glioma cells could extend their leading 
cytoplasmic processes through membrane pores, as a function of actin dynamics alone, but 
they required myosin IIA/B to generate additional cytoplasmic contractile forces to push the 
nucleus through pores having a smaller diameter (Beadle et al., 2008). 
 
 
Fig. 5. Boyden chamber assay. (A) Transwell migration assays are composed of a well insert 
with a porous filter bottom that temporarily separates the cell solution from the test 
solution. (B) The filter has randomly distributed microscale diameter pores as shown by 
arrows. (C) Invasive Daoy cells on the underside of the filter stained and imaged for 
migration analysis. Scale bar = 50 μm.  
A study that looked at the inhibitory effect of dietary-derived flavonols on the HGF receptor 
c-Met activity suggests that such an effect may contribute to the chemopreventive properties 
of these molecules (Labbe et al., 2009). The authors showed that the flavonols quercetin, 
kaempferol, and myricetin inhibited HGF/c-Met signaling in MB, preventing the formation 
of actin-rich membrane ruffles and resulting in the inhibition of c-Met-induced cell 
migration in Boyden chambers (Labbe et al., 2009). Furthermore, quercetin and kaempferol 
also strongly diminished HGF-mediated Akt activation (Labbe et al., 2009). 
While investigating the effect of ionizing irradiation on the invasiveness of glioma cells via 
transwell assays, Park and colleagues reported increased Matrigel™ invasion of PTEN null 
gliomas, U-251 MG and U-373 MG, as a result of elevated levels irradiation treatment, which 
the group suggested correlates with increases in MMP-2 secretion (Park et al., 2006). 
Similarly, Wild-Bode and colleagues found that the sublethal irradiation doses of 1, 3, and 6 
Gy increased the chemotactic migration and invasion of three different human glioma cell 
lines with increasing dosage (Wild-Bode et al., 2001). Similarly to glioma, radiation 
enhanced invasion and migration of 7 Gy irradiated MB compared to non-irradiated MB 
cells, as assessed via Boyden chamber assays (Nalla et al., 2010). Increased expression of 
urokinase-type plasminogen activator (uPA) and its receptor (uPAR), focal adhesion kinase 
(FAK), N-cadherin and integrin subunits (e.g., ǂ3, ǂ5 and ǃ1) was detected in irradiated cells. 
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Conversely, down-regulation of uPAR reduced the radiation-induced adhesion, migration 
and invasion of the irradiated cells, primarily by inhibiting phosphorylation of FAK, Paxillin 
and Rac-1/Cdc42 (Nalla et al., 2010). 
Transwell assays were also used to study the activated RTK-dependent MB migration. 
These studies have shown that MB migration is dependent on estrogen-receptor (Belcher et 
al., 2009), c-Met (Guessous et al., 2010), and PDGFR-ǃ activation (Yuan et al., 2010). Via a 
combination of wound-healing assays and modified Boyden chamber assays, two groups 
showed that PDGF-induced overexpression of Rac1, a Rho GTPase, is involved in MB cell 
migration and invasion, whereas knockdown of Rac1 expression dramatically inhibited 
migration and invasion of MBs (Chen et al., 2011; Yuan et al., 2010). These findings may 
promote the evaluation of Rac1 as a novel therapeutic agent impairing medulloblastoma 
PDGF-induced migration/invasion. Additional work has demonstrated that PDGFR-ǃ 
activity may guide the migration of MB by transactivating EGFR (Abouantoun and 
MacDonald, 2009). These results are of particular interest, since EGFR is known to be 
expressed in GNPCs of the human cerebellum, participating in its normal development and 
function (Seroogy et al., 1995). Recently, the multifunctional signaling protein neurotrophin 
receptor p75NTR was shown to be a central regulator for GBM (Johnston et al., 2007) and MB 
spinal invasion while Ǆ-secretase inhibitor, which blocks p75NTR proteolytic processing, 
significantly abrogates p75NTR induced MB migration and invasion in vitro and in vivo 
(Wang et al., 2010). 
The transwell assays, even though used commonly for cell migration experiments, often 
yield inconsistent results across research groups due to the experimental individual assay 
modifications made by each group. For example, the ECM component used for filter coating 
can serve as a chemoattractant via integrin signaling (triggered by the interaction with 
laminin contained in the matrix), or via the release of growth factors embedded in the 
matrix itself. Although a reduced-growth factor form of Matrigel™ is generally used (i.e. 
reduced amounts of the above mentioned molecules are present in the matrix), there are a 
plethora of ECM proteins and growth factors, reconstituted along with Matrigel™, whose 
concentrations may vary with each batch purchased, and cause variations in the results. Yet, 
perhaps the largest shortcoming of transwell assays with respect to quantifying migration is 
that the cytokine microenvironments they create are very complex to model mathematically. 
Diffusion gradients of molecules across the membrane pores are difficult to measure or 
predict analytically, with or without matrix coating. Among in vitro approaches, 
microfluidics has proven to be a powerful technology to study cell migration over the past 
few years, due to the ability to generate a precise cell microenvironment that can be both 
predicted by analytical models and validated experimentally (Kong et al., 2010), as 
summarized further on. 
5.4 Microdevices 
Advances in microfabrication have made microfluidics systems easier to design and 
manufacture. Currently, the majority of devices are constructed of polydimethylsiloxane 
(PDMS) via soft lithography pioneered by the Whitesides group (McDonald and Whitesides, 
2002). The polymer allows the construction of systems with high transparency and low 
thickness that are highly-compatible with biological microscopy. As dissemination of glioma 
or MB cells can often follow the path of white matter tracks or other heterogeneous 
structures, mechanical properties of the microenvironment play significant roles in tumor 
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cell locomotion (Guck et al., 2010). PDMS microsystems pre-define the cell migratory path 
within microsized channels that mimic in vivo conditions. As such, cell motility and 
directionality can be examined and measured via conventional time-lapse imaging. 
Pioneering applications of microdevices for cancer cell study utilized microchannels coated 
and filled with various extracellular matrixes in 2D and 3D (Schoen et al., 2010; Sung et al., 
2009) to illustrate the selectivity of cancer cell migration on distinct ECM, as well as to 
measure traction forces and leading edge protrusions of a variety of cancer cell types (Li et 
al., 2009). More recently, biomedical engineers have begun to develop systems that generate 
linear and non-linear cytokine gradients in order to more accurately investigate the 
chemotactic behavior of cells derived from primary tumors.  
Establishment of steady-state gradient profiles has been examined using flow-based 
gradient generators, diffusion-based gradient generators, as well as hybrid generators 
(mixture of convection and diffusion). One of the original microdesigns for migration study 
was developed by Li Jeon and colleagues, in a gradient mixer design initially used for 
neutrophil chemotaxis (Li Jeon et al., 2002). This device contains multiple inlets that enable 
the loading of different ligand solutions that are then mixed in channels perpendicular to 
the flow direction (Figure 6A). Subsequently, a variety of system designs have been 
developed to generate alterative gradient shapes for further chemotaxis study (Kim et al., 
2010). In such flow-based designs, two concentrations of biomolecules flow separately into a 
network of microchannels, where mixers are patterned to combine adjacent streams via 
convection in order to generate a chemical gradient. While flow-based devices are able to 
finely control the spatiotemporal resolution of the gradient, they require constant flow rates 
of reagents that remove molecules secreted from cells that are critical to regulation of tumor 
cell migration (Huang et al., 2011). 
 
 
Fig. 6. Schematics of microdevices currently used to generate concentration gradients  
(not to scale). The flow mixer device was first proposed by Li Jeon and colleagues to create 
highly controllable concentrations along specific distances via continuous convective flow.  
(A) Schematic representation of a premixing gradient generating device pioneered by Li 
Jeon and colleagues. (B) A hybrid microlane system uses interconnected reservoirs to create 
concentration gradients via both convection and diffusion. The microchannel approximately 
measures 13 mm in length, 90 μm in depth and 100 μm in width (averaged with the upper side 
of 95 μm and the lower side of 105 μm), as its semi-hemispherical cross-section shown in inset. 
(Courtesy of Kong et al., 2010) 
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Subsequent microdevice designs now often generate soluble gradients by using passive 
diffusion. These systems can eliminate fluid flow near the surroundings of cells by using 3D 
hydrogels or high resistance channels so that transport occurs predominantly via diffusion 
(Beebe et al., 2002). In this configuration, two reservoirs are typically used to maintain given 
chemical concentration in a specified sink and source. Diffusion along adjoining 
microchannels then facilitates the formation of a concentration gradient between the 
reservoirs that enables cells to migrate along the defined gradient (Paguirigan and Beebe, 
2008). While these systems eliminate the flow stresses imposed upon cells in flow-based 
devices, they require several hours to generate desired gradients, and rapid adjustment to 
the gradient profile is often difficult if not impractical. As a result, hybrid microsystems 
have been developed to enable the use diffusion with a minute level of convection to bolster 
formation of a desired gradient. For example, our group was able to generate steady-state 
gradients that were stable for 2-3 days using a bridge design and by exploiting the ultra-low 
bulk velocities generated by density differences between the reagents used (Figure 6B) 
(Kong et al., 2010).  
The development of microfluidic platforms that incorporate real-time control of cell imaging 
and measurement of chemotactic concentration gradients is highly needed for 
understanding the dynamics of brain tumor interactions, an area which remains relatively 
unexplored when the majority of microfluidic studies focus on measurement of end-point 
cellular responses. 
6. Future prospects of anti-invasive brain tumor therapy 
The impetus for the development of anti-migratory therapeutic agents for brain tumors has 
been the desire to ease the manageability of the disease, by arresting tumor cells to their 
primary local environment. Such strategies can reduce the need to utilize the so-called 
“Search and Destroy” approach that is the currently suggested clinical necessity. Elucidation 
of possible mechanisms used by diffusely infiltrative glioma and MB cells will enable a 
better understanding of how to render these cells static, while providing targets for the 
development of pharmacological products capable of such a task.   
More recently it has been suggested that enhancing the recruitment of endogenous 
progenitors toward tumor masses will aid in restoring the brain regions that have been 
resected or lost via necrosis (Cayre et al., 2009). Neural stem cells (NSCs) have aroused 
attention in the field of neurooncology as delivery vehicles of therapeutic genes. In addition 
to their multipotential capabilities that allow them to differentiate into neurons, astrocytes 
and oligodendrocytes, NSCs are also characterized by their remarkable capability to migrate 
through the brain (Gage, 2000; Yandava et al., 1999). The ability of implanted NSCs to 
distribute themselves throughout the tumors and follow invasive glioma cells has raised the 
idea of their therapeutic potential in targeting invasive glioma cells in vivo (Aboody et al., 
2000; Staflin et al., 2009). Shimato and colleagues demonstrated in vitro that human NSCs 
exhibited extensive tropism for MB cells (Shimato et al., 2007). Using leptomeningeal 
dissemination mouse models, they confirmed in vivo that NSCs were able to distribute 
diffusely to MB cells that had spread throughout the entire spinal cord after implantation in 
the cisterna magna, and that genetically transformed NSCs functioned effectively in killing 
MB cells (Shimato et al., 2007). Similarly, genetically-modified NSCs were delivered intra-
cranially and shown to target MBs (Kim et al., 2006). Recently, it was shown that human 
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umbilical cord blood-derived stem cells can integrate into human MB after local delivery, 
and that MMP-2 expression by the tumor cells mediates this response through the 
SDF1/CXCR4 pathway (Bhoopathi et al., 2011). These results offer a new promising 
therapeutic modality that uses human stem cells for targeting intra-cranial as well as 
leptomeningeal dissemination of MBs. 
Although significant results are being generated from the stem cell community, brain tumor 
researchers have only recently begun to reflect on the specifics of glial progenitor 
recruitment as a form of treatment for the disease. Glial progenitor cells have shown 
increased healing potential after supplementing the cultures with exogenous concentrations 
of VEGF D when compared to controls (Kranich et al., 2009). Using transwell assays, a dose 
dependent invasive response of murine neural stem cells towards human glioma 
conditioned media (Heese et al., 2005) and bi-potential O-2A progenitors toward PDGF 
(Gallo et al., 1996) has been displayed. 
Ideally, as has been the case in previous years, the focus should be to target cytokines and 
their cognate receptors involved in glioma and MB chemotaxis signaling events.  Moving 
forward, the community is in great need of technologies and strategies that can both 
approximate the chemical microenvironment present in the in vivo brain, and replicate these 
environments in vitro. In so doing, migration strategies can be developed that examine how 
combinations of cytokine and/or pharmacological cocktails can be used to limit the 
diffusive migration of tumor-derived cells into healthy brain. 
7. Conclusion 
The migration of glioma and medulloblastoma tumor cells into healthy brain tissue is a 
critical, yet poorly-understood, component of the tumor invasion and metastasis that 
contributes to poor patient prognosis. Extensive in vivo studies of brain tumors have 
generated invaluable data to elucidate the molecular alterations and genetic backgrounds 
present in diseased cells, the signaling mechanisms cells use to communicate with their 
surrounding microenvironment, and the characteristic patterns of dissemination used by 
specific tumor cell types. Additionally, in vitro studies of brain tumor-derived cells have 
established the chemotactic potential of various cytokines and extracellular matrixes, 
evaluated the effectiveness of pharmaceutical cocktails on tumor growth, as well as enabled 
fundamental measurement of motility and directionality in tumor cell samples. While the 
majority of research efforts to date have focused on the origin and nature of tumorigenesis 
in glioma and medulloblastoma, the community is now beginning to examine the integrated 
role of cell migration in tumor growth and dissemination. Future research is needed to 
examine the existence and characteristics of tumor cell populations with highly motile 
phenotypes in order to establish cell migration as a viable therapeutic target, and start 
designing treatment regimens based on cell migratory behaviors.  
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